Anika Therapeutics, Inc. (ANIK)

Market Cap	377.59M
Revenue (ttm)	166.66M
Net Income (ttm)	-82.67M
Shares Out	14.64M
EPS (ttm)	-5.64
PE Ratio	n/a
Forward PE	1,685.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,868
Open	25.90
Previous Close	25.95
Day's Range	25.67 - 26.16
52-Week Range	16.54 - 28.13
Beta	0.75
Analysts	Buy
Price Target	29.50 (+14.39%)
Earnings Date	May 8, 2024

About ANIK

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 29, 1993
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIK

Financial Performance

In 2023, ANIK's revenue was $166.66 million, an increase of 6.67% compared to the previous year's $156.24 million. Losses were -$82.67 million, 456.3% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is $29.5, which is an increase of 14.39% from the latest price.

Price Target

$29.5

(14.39% upside)

Analyst Consensus: Buy